Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Catheter-based renal denervation for treatment of hypertension

After the initial unprecedented enthusiasm for catheter-based renal denervation for the treatment of resistant hypertension, the negative results of the sham-controlled SYMPLICITY HTN-3 trial1 with the single-electrode radiofrequency Symplicity catheter have cast major doubts on the efficacy of this technique to treat these patients. Various factors might have contributed to these negative results.2 By contrast, the DENERHTN trial,3 which compared renal denervation plus stepped care standardised antihypertensive treatment with stepped care standardised antihypertensive treatment alone in patients with resistant hypertension, although not sham-controlled, reported a 5–6 mm Hg difference in daytime ambulatory systolic blood pressure (SBP) in favour of renal denervation at 6 months.